Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
44
AZNCF Quote, Financials, Valuation and Earnings
Last price:
$131.12
Seasonality move
:
-1.44%
Day range:
$126.40 - $132.77
52-week range:
$118.16 - $175.00
Dividend yield:
2.26%
P/E ratio:
31.40x
P/S ratio:
3.99x
P/B ratio:
4.98x
Volume:
3.4K
Avg. volume:
3.1K
1-year change:
0.17%
Market cap:
$203B
Revenue:
$45.8B
EPS (TTM):
$4.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZNCF
AstraZeneca PLC
|
$13.1B | -- | 17.56% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$2M | -$0.41 | -- | -2.08% | $47.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZNCF
AstraZeneca PLC
|
$130.92 | -- | $203B | 31.40x | $0.98 | 2.26% | 3.99x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.58 | $3.50 | $148.1M | -- | $0.00 | 0% | 0.81x |
|
AUTL
Autolus Therapeutics PLC
|
$2.25 | -- | $598.8M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.29 | -- | $2.5M | -- | $0.00 | 0% | 3.87x |
|
NCNA
NuCana PLC
|
$1.21 | $64.50 | $4.7M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$45.28 | $47.29 | $3.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZNCF
AstraZeneca PLC
|
42.54% | -0.390 | 12.58% | 0.71x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
VRNA
Verona Pharma PLC
|
47.91% | -0.070 | 5.1% | 12.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZNCF
AstraZeneca PLC
|
$10.5B | $2.1B | 9.41% | 16.72% | 16.85% | $2B |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZNCF or ADAP?
Adaptimmune Therapeutics PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -43.07%. AstraZeneca PLC's return on equity of 16.72% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital AZNCFAstraZeneca PLC77.29% $0.91 $70.9B ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About AZNCF or ADAP?
AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 291.62%. Given that Adaptimmune Therapeutics PLC has higher upside potential than AstraZeneca PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNCFAstraZeneca PLC0 0 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is AZNCF or ADAP More Risky?
AstraZeneca PLC has a beta of 0.445, which suggesting that the stock is 55.459% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock AZNCF or ADAP?
AstraZeneca PLC has a quarterly dividend of $0.98 per share corresponding to a yield of 2.26%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZNCF or ADAP?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. AstraZeneca PLC's net income of $1.4B is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.40x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.99x versus 0.81x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNCFAstraZeneca PLC3.99x 31.40x $13.6B $1.4B ADAPAdaptimmune Therapeutics PLC0.81x -- $40.9M -$17.6M
-
Which has Higher Returns AZNCF or AUTL?
Autolus Therapeutics PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -522.15%. AstraZeneca PLC's return on equity of 16.72% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital AZNCFAstraZeneca PLC77.29% $0.91 $70.9B AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About AZNCF or AUTL?
AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 364.44%. Given that Autolus Therapeutics PLC has higher upside potential than AstraZeneca PLC, analysts believe Autolus Therapeutics PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNCFAstraZeneca PLC0 0 0 AUTLAutolus Therapeutics PLC7 2 0 -
Is AZNCF or AUTL More Risky?
AstraZeneca PLC has a beta of 0.445, which suggesting that the stock is 55.459% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.984, suggesting its more volatile than the S&P 500 by 98.37%.
-
Which is a Better Dividend Stock AZNCF or AUTL?
AstraZeneca PLC has a quarterly dividend of $0.98 per share corresponding to a yield of 2.26%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZNCF or AUTL?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. AstraZeneca PLC's net income of $1.4B is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.40x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.99x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNCFAstraZeneca PLC3.99x 31.40x $13.6B $1.4B AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns AZNCF or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 16.72% beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AZNCFAstraZeneca PLC77.29% $0.91 $70.9B BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About AZNCF or BDRX?
AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNCFAstraZeneca PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is AZNCF or BDRX More Risky?
AstraZeneca PLC has a beta of 0.445, which suggesting that the stock is 55.459% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock AZNCF or BDRX?
AstraZeneca PLC has a quarterly dividend of $0.98 per share corresponding to a yield of 2.26%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZNCF or BDRX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. AstraZeneca PLC's net income of $1.4B is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.40x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.99x versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNCFAstraZeneca PLC3.99x 31.40x $13.6B $1.4B BDRXBiodexa Pharmaceuticals PLC3.87x -- -- --
-
Which has Higher Returns AZNCF or NCNA?
NuCana PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 16.72% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AZNCFAstraZeneca PLC77.29% $0.91 $70.9B NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About AZNCF or NCNA?
AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 5230.58%. Given that NuCana PLC has higher upside potential than AstraZeneca PLC, analysts believe NuCana PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNCFAstraZeneca PLC0 0 0 NCNANuCana PLC1 2 0 -
Is AZNCF or NCNA More Risky?
AstraZeneca PLC has a beta of 0.445, which suggesting that the stock is 55.459% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.593%.
-
Which is a Better Dividend Stock AZNCF or NCNA?
AstraZeneca PLC has a quarterly dividend of $0.98 per share corresponding to a yield of 2.26%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZNCF or NCNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than NuCana PLC quarterly revenues of --. AstraZeneca PLC's net income of $1.4B is higher than NuCana PLC's net income of -$5.9M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.40x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.99x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNCFAstraZeneca PLC3.99x 31.40x $13.6B $1.4B NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns AZNCF or VRNA?
Verona Pharma PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -763.91%. AstraZeneca PLC's return on equity of 16.72% beat Verona Pharma PLC's return on equity of -74.15%.
Company Gross Margin Earnings Per Share Invested Capital AZNCFAstraZeneca PLC77.29% $0.91 $70.9B VRNAVerona Pharma PLC90.35% -$0.56 $250.5M -
What do Analysts Say About AZNCF or VRNA?
AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 4.43%. Given that Verona Pharma PLC has higher upside potential than AstraZeneca PLC, analysts believe Verona Pharma PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNCFAstraZeneca PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is AZNCF or VRNA More Risky?
AstraZeneca PLC has a beta of 0.445, which suggesting that the stock is 55.459% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.579%.
-
Which is a Better Dividend Stock AZNCF or VRNA?
AstraZeneca PLC has a quarterly dividend of $0.98 per share corresponding to a yield of 2.26%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZNCF or VRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Verona Pharma PLC quarterly revenues of $5.6M. AstraZeneca PLC's net income of $1.4B is higher than Verona Pharma PLC's net income of -$43M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.40x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.99x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNCFAstraZeneca PLC3.99x 31.40x $13.6B $1.4B VRNAVerona Pharma PLC-- -- $5.6M -$43M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
